Endocrine-disrupting chemicals (EDCs) are ubiquitous environmental contaminants that interfere with hormone signalling and are increasingly linked to adverse reproductive outcomes. This viewpoint highlights emerging evidence that EDC exposure disrupts both …
Endometriosis (EMs) is a common gynecological disorder in women of reproductive age, often presenting with pelvic pain and infertility. Its progression is closely linked to estrogen levels. While hormonal therapies …
The aim was to explore the lived experiences of women diagnosed with endometriosis and receiving care in Spain to understand its impact across multiple areas of their lives. This qualitative …
Endometriosis is an estrogen-dependent disorder characterized by chronic inflammation, immune dysregulation, and altered hormone metabolism. Although gut microbiota-derived metabolites have been implicated in shaping immune microenvironments and lesion development, the …
Endometriosis is a chronic inflammatory disorder lacking definitive laboratory diagnostic markers. Angiopoietin-like protein-4 (ANGPTL4) is a protein involved in the regulation of angiogenesis and inflammation. The aim of the present …
Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …
Endometriosis (EMs) is a widespread gynecological disease, affecting approximately 6-10% of females of child-bearing age. Despite its significant influence on women's health, the specific pathophysiology remains unclear. The enrichment of …